Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•14/08/2026•07:00 ET
0
Whiz Insights
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026
Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in schizophrenia with clinical data expected in fourth quarter of 2026 and second half of 2026, respectively
Get started
Create a free account to read the full story.